• Adverse events (AEs) (including acute IPF exacerbation and pneumonia), clinical lab tests, electrocardiograms, early discontinuations, death. [ Time Frame: Week 1, 2, 4, 6, 12, and every 12 weeks thereafter until the end of the study ] [ Designated as safety issue: Yes ]
  

• Percent predicted forced vital capacity (FVC, Percent predicted hemoglobin (HB)-corrected Carbon monoxide diffusing capacity (DLCO) [ Time Frame: Weeks 2, 4, 6, 12, and every 12 weeks thereafter until the end of the study ] [ Designated as safety issue: No ]
  

This is an open-label, multicenter, extension study for patients with IPF who complete the CAPACITY Trials (PIPF-004 and PIPF 006). Eligible patients must complete the Final Follow-Up Visit for the CAPACITY studies and meet all of the eligibility criteria noted in the protocol. Only the sites that participate in the CAPACITY studies will be eligible to participate in this study.

The data from the CAPACITY Trials will remain blinded during the PIPF-012 enrollment period. Therefore, all patients will be treated as if they were taking placebo in the CAPACITY studies, and at the start of PIPF-012 will escalate their dose of pirfenidone.

The duration of treatment for each patient will be variable and will continue until pirfenidone is commercially available in a geographic region, the study is terminated by the sponsor for reasons outlined in the protocol, or approximately 2.5 years have elapsed since the patient's first dose of pirfenidone, whichever is shortest.